NEW YORK (GenomeWeb News) – Cellumen said yesterday that it has spun off its personalized medicine unit, called Cernostics Pathology.
Pittsburgh-based Cellumen said that Cernostics will provide digital imaging pathology and tissue-based diagnostics products and services for personalized medicine applications. It added that the spinout would build on Cellumen’s current collaborations with partners, such as the Mayo Clinic and Foundation, in developing a breast cancer diagnostic and theranostic test.
“Cellumen will maintain its core business by focusing on the interface between early drug discovery and early toxicity testing,” Lansing Taylor, CEO of Cellumen, said in a statement.
Taylor will serve as chairman of Cernostics Pathology, and Michel Nederlof will join the new firm as president and chief technology officer. Nederlof recently was the founder and president of QED Imaging, which is now part of Media Cybernetics.